Streetwise Expert Interviews

Raghuram Selvaraju

Not Your Father's Diagnostics: Ram Selvaraju on How Molecular Genomics Invigorate the Sector

An old investment principle says the equity upside of diagnostics and tools companies can't hold a candle to that of small biotech drug developers. Managing Director and Head of Equity Healthcare Research Raghuram "Ram" Selvaraju of Aegis Capital begs to differ. His research has uncovered small- and micro-cap companies developing sophisticated platforms in the molecular diagnostics space that are destined for significant revenue growth and profits. In his first of three interviews with The Life Sciences Report, Selvaraju lays out a handful of names with powerful technologies on the cusp of investor acceptance as huge growth plays. (12/5/13) More >


Read more Streetwise interviews...

including Eight Catalyst-Driven Biotechs Ready to Advance: Michael Hay and Jocelyn August (11/26/13) More >

Newsletter Briefs

"DRIO is developing a very interesting approach to diagnostics at the level of data capture." (12/5/13) LabStyle Innovations Corp. - The Life Sciences Report Interview with Ram Selvaraju More >

"NBS has the potential to become a major player in the stem cell industry." (11/25/13) NeoStem Inc. - Glen Woods, Seeking Alpha More >

"ATHX's MultiStem phase 2 data are going to be very important for investors if the trial is positive for patients." (11/26/13) Athersys Inc. - The Life Sciences Report Interview with Michael Hay More >

"I am encouraged by CYTR's interim clinical trial results to date." (11/19/13) CytRx Corp. - John Mylant, Seeking Alpha More >

"The year 2014 is clearly going to be a defining one for ATHX." (11/18/13) Athersys Inc. - Bio StocksElite, Seeking Alpha More >

"BDSI is quite an interesting company; we expect Bunavail to be approved." (11/26/13) BioDelivery Sciences International Inc. - The Life Sciences Report Interview with Michael Hay More >

Expert Analysis

"Results in 2014 from ATHX's phase 2 studies could rerate the stock." (12/2/13) Athersys Inc. - Christian Glennie, Edison Investment Research More >

"VRS' Aura continues to be recognized as one of the leading novel medical technologies." (12/2/13) Verisante Technology Inc. - Brian Marckx, Zacks Small-Cap Research More >

"Major alliances reduce execution risk for MSB's late-stage pipeline." (11/26/13) Mesoblast Ltd. - Michael Aitkenhead, Edison Investment Research More >

"We anticipate a CE mark for VNRX's NuQ technology by next year." (11/25/13) VolitionRx Ltd. - Brian Marckx, Zacks Small-Cap Research More >

"CTH's concept is simple and the path to commercialization has been validated; we like the story." (11/26/13) Cynapsus Therapeutics Inc. - Jason Napodano, Seeking Alpha More >

"Walgreens' procurement of OCLS' Puracyn products is positive." (11/25/13) Oculus Innovative Sciences Inc. - Dan Trang, Stonegate Securities More >